Heat Biologics (HTBX) aims to be the vaccine winner
Heat Biologics (HTBX) currently trades at $0.51 and has fallen by 5.72% today. Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient’s immune system against cancer and other diseases using its proprietary gp96 platform to activate CD8+ “Killer” T-cells. Heat has completed enrollment in its Phase 2 clinical trial for advanced non-small cell lung cancer with its gp96-based HS-110 therapeutic vaccine. HS-110 is the company’s first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient’s T-cells.
Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information. Heat’s COVID-19 Advisory Board was established with leading thought leaders to propel Heat’s COVID-19 vaccine and COVID-19 diagnostic programs. The combined Advisory Board has expertise in areas of coronavirus and related respiratory virus biology and infection, immunotherapy, and vaccines. Heat recently announced a research collaboration with the University of Miami Miller School of Medicine to develop a vaccine leveraging Heat’s proprietary gp96 platform designed to target the SARS-CoV-2 coronavirus that causes COVID-19. The high forecast for Heat Biologics is $5.00 and the low is $2.00. Notably, the company’s market cap is $40.64 million with a 52 week high of $1.27 and a 52 week low of $0.20.